Additional investigations will be required to elucidate the mechanisms by which Sirt2 delays c-MYC-driven HCC tumorigenesis in vivo, possibly through a regulatory pathway involving ubiquitination as previously reported [16]. This evidence concerns the gene MYC and hepatocellular carcinoma.